(22R,24S)-cholest-5-ene-3β,22,24-triol | 220006-95-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (22R,24S)-cholest-5-ene-3β,22,24-triol
• 英文别名: 22(R),24(S)-Dihydroxycholesterol；(2S,3R,5S)-2-[(3S,8S,9S,10R,13S,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylheptane-3,5-diol
• CAS: 220006-95-1
• 化学式: C₂₇H₄₆O₃
• 分子量: 418.66
• InChiKey: QJVNNUASHVUOBN-ASVFFUHVSA-N

物化性质

• 沸点：
  559.9±25.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (22R,24S)-cholest-5-ene-3β,22,24-triol 在 D(+)-10-樟脑磺酸 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 1,4-二氧六环 、 丙酮 为溶剂， 反应 6.0h， 生成 (22R,24S)-22,24-isopropylidenedioxycholesta-4,6-dien-3-one
  参考文献：
  名称：

  摘要：

  Steroidal 1,4,6-trien-3-ones which are precursors of 1alpha-hydroxylated vitamin D and its analogs were synthesized starting from 3beta-hydroxy-Delta(5)-20-dihydroisoxazolyl steroids and their open-chain derivatives.

  DOI：

  10.1023/a:1016373807105
• 作为产物：
  描述：

  (E)-(R)-6-[(3S,8S,9S,10R,13R,14S,17R)-3-(tert-Butyl-dimethyl-silanyloxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-hept-4-en-3-one 在 sodium hydroxide 、 samarium diiodide 、 四丁基氟化铵 、 双氧水 、 儿萘酚硼烷 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 3.0h， 生成 (22R,24S)-cholest-5-ene-3β,22,24-triol
  参考文献：
  名称：

  Simple, stereocontrolled syntheses of 24(S),25-epoxy-22(R)-hydroxycholesterol, 22(R),24(S)-dihydroxycholesterol and diastereomers, new ligands for binding and activation of LXRs

  摘要：

  Described herein are stereocontrolled syntheses of a series of sidechain oxygenated cholesterols for the study of binding and activation of nuclear receptors of the LXR family. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(98)02182-0

文献信息

• Treatment for age-related macular degeneration (AMD)
  申请人：——

  公开号：US20030162758A1

  公开（公告）日：2003-08-28

  The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.

  本发明利用与动脉粥样硬化类似的致病机制的调节来治疗老年性黄斑变性。在更具体的实施方案中，反向胆固醇转运成分，如转运体和高密度脂蛋白组分，被用作老年性黄斑变性的诊断和治疗靶标。在一个具体的实施方案中，视网膜色素上皮和/或布鲁氏膜的脂质含量降低。
• Treatments for age-related macular degeneration (AMD)
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20030229062A1

  公开（公告）日：2003-12-11

  The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, reverse cholesterol transport components, such as transporters and HDL fractions, are utilized as diagnostic and therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or Bruch's membrane is reduced.

  本发明利用与动脉粥样硬化类似的致病机制的调节来治疗老年性黄斑变性。在更具体的实施方案中，反向胆固醇转运成分，如转运体和高密度脂蛋白组分，被用作老年性黄斑变性的诊断和治疗靶标。在一个具体的实施方案中，视网膜色素上皮和/或布鲁氏膜的脂质含量降低。
• Compositions and methods for modulating HDL cholesterol and triglyceride levels
  申请人：——

  公开号：US20040137423A1

  公开（公告）日：2004-07-15

  The invention provides methods for identifying agents that modulate HDL-levels in animals by evaluating the ability of LXR-modulating agents to increase ABCA1-gene expression in a cell as well as using such agents to treat conditions involving lower than normal HDL-levels, higher than normal triglyceride levels and the like.

  本发明提供了通过评估 LXR 调节药剂增加细胞中 ABCA1 基因表达的能力，以及使用此类药剂治疗高密度脂蛋白水平低于正常、甘油三酯水平高于正常等病症，从而确定调节动物体内高密度脂蛋白水平的药剂的方法。
• COMPOSITIONS AND METHODS FOR MODULATING HDL CHOLESTEROL AND TRIGLYCERIDE LEVELS
  申请人：University of British Columbia

  公开号：EP1239848A2

  公开（公告）日：2002-09-18
• METHODS FOR TREATING DISORDERS OF THE NERVOUS AND REPRODUCTIVE SYSTEMS
  申请人：Xenon Genetics, Inc.

  公开号：EP1397385A2

  公开（公告）日：2004-03-17